| Pegasys (pegylated interferon α -2a) / Roche |
NCT00514111: Factors Associated to Success of Hepatitis C Therapy |
|
|
| Completed | N/A | 100 | RoW | pegylated-interferon, conventional-interferon, ribavirin, Pegasys, PegIntron, Ribavirin | UPECLIN HC FM Botucatu Unesp | Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted | 07/08 | 12/08 | | |
NCT02850289: APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin |
|
|
| Completed | N/A | 385 | Canada | Pegylated interferon (PEG-INF) alfa-2a, PEGASYS, Ribavirin, COPEGUS | Hoffmann-La Roche | Hepatitis C, Chronic | 10/08 | 10/08 | | |
DICO, NCT00909129: Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment |
|
|
| Completed | N/A | 25 | Europe | pegylated interferon-alpha (Pegasys), Pegasys (interferon), ribavirin (COPEGUS), COPEGUS (RIBAVIRIN) | Karolinska Institutet, The Swedish Research Council, Hoffmann-La Roche | Human Immunodeficiency Virus, Chronic Hepatitis C | | | | |
NCT00571714: Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients |
|
|
| Withdrawn | N/A | 0 | NA | Peginterferon alpha-2a and ribavirin, Pegasys, Copegus, Peginterferon alpha-2a , ribavirin and betaine, Copegas | University of Nebraska | Chronic Hepatitis C | 03/10 | 03/10 | | |
NCT00700401: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). |
|
|
| Completed | N/A | 262 | RoW | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/10 | 11/10 | | |
NCT01066793: PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b |
|
|
| Completed | N/A | 2343 | Europe | Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/11 | 05/11 | | |
|
NCT01464008: The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C |
|
|
| Completed | N/A | 297 | RoW | Pegylated interferon alfa-2a and ribavirin, Pegasys®; Roche, Basel, Switzerland | Beijing Ditan Hospital | Chronic Hepatitis C | 05/11 | 09/11 | | |
NCT02726022: A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels |
|
|
| Completed | N/A | 114 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 07/11 | 07/11 | | |
NCT01070550: PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) |
|
|
| Completed | N/A | 4680 | Canada, Europe, RoW | Peginterferon alfa-2a (Pegasys®) | Hoffmann-La Roche | Hepatitis C, Chronic | 07/11 | 07/11 | | |
|
|
NCT01066819: PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b |
|
|
| Completed | N/A | 1656 | US | Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®] | Hoffmann-La Roche | Hepatitis C, Chronic | 08/11 | 08/11 | | |
MEN_EPID, NCT01402583: Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C |
|
|
| Completed | N/A | 1000 | Europe | PEG IFN/Ribavirin, Pegylated IFN 2a Pegasys, Pegylated IFN 2b PegIntron, Copegus, Rebetol | Prof. Facchinetti Fabio, Merck Sharp & Dohme LLC | Chronic Hepatitis C | 08/11 | 09/11 | | |
NCT00724451: Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) |
|
|
| Completed | N/A | 1128 | Europe | Peginterferon alfa-2b, SCH 054031, PegIntron, Ribavirin, SCH 018908, Copegus, Rebetol, Virazole, RBV, Peginterferon alfa-2a, Pegasys | Merck Sharp & Dohme LLC | Hepatitis C, Hepatitis C, Chronic | 10/11 | 10/11 | | |
| Completed | N/A | 100 | Europe | Interferon and ribavirin, Pegasys (ATC Code: L03AB11) and Copegus (ATC Code: J05AB04) | Aarhus University Hospital | Hepatitis C, Chronic, Cognition Disorders, Fatigue Syndrome, Chronic, Major Depressive Disorder | 11/12 | 11/12 | | |
NCT02113631: Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir |
|
|
| Completed | N/A | 50 | US | Telaprevir, INCIVEK, Boceprevir, Victrelis, Peg-IFN, Peg-Interferon alfa-2a, Pegasys, Ribavirin, Copegus | Louis Stokes VA Medical Center | Hepatitis C, Chronic, Cirrhosis | 04/13 | 04/13 | | |
NCT01200225: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | N/A | 1155 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
NCT01625793: Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes |
|
|
| Withdrawn | N/A | 0 | US | Interferon-alpha, Pegintron®, Schering Plough, PEGASYS®, Roche | University of Arizona, Emory University, National Center for Complementary and Integrative Health (NCCIH) | Hepatitis C | 07/13 | 07/13 | | |
NCT02106156: Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) |
|
|
| Completed | N/A | 10228 | Europe | Pegylated interferon alfa-2a, Pegasys®, Ribavirin, Copegus® | Hoffmann-La Roche | Chronic Hepatitis C | 09/13 | 09/13 | | |
NCT01726400: In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia |
|
|
| Completed | N/A | 15 | RoW | Pegylated interferon alpha, pegasys, pegatron, Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole | Fremantle Hospital and Health Service | Hepatitis C | 01/14 | 07/14 | | |
NCT02557646: An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C |
|
|
| Completed | N/A | 697 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 03/14 | 03/14 | | |
NCT01508130: An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 |
|
|
| Completed | N/A | 672 | US | | Hoffmann-La Roche | Hepatitis C, Chronic | 03/14 | 03/14 | | |
OPTIM, NCT01884402: Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 |
|
|
| Completed | N/A | 770 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Hepatitis C, Chronic | 05/14 | 08/14 | | |
NCT02556307: A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients |
|
|
| Completed | N/A | 270 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 07/14 | 07/14 | | |
NCT01639547: Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C |
|
|
| Terminated | N/A | 410 | RoW | Peginterferon alfa-2a plus Ribavirin, PEGASYS® plus ROBATROL® | Chang Gung Memorial Hospital | Chronic Hepatitis C | 07/14 | 07/14 | | |
NCT01392742: An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin |
|
|
| Completed | N/A | 443 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 07/14 | 07/14 | | |
PEGHOPE, NCT01416610: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy |
|
|
| Completed | N/A | 88 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 10/14 | 10/14 | | |
NCT02515279: An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria |
|
|
| Completed | N/A | 463 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C | 12/14 | 12/14 | | |
NCT01750216: An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 |
|
|
| Completed | N/A | 196 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 01/15 | 01/15 | | |
NCT02118597: An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients |
|
|
| Terminated | N/A | 19 | Europe | Boceprevir, Victrelis, Simeprevir, Olysio, Pegylated Interferon (Peginterferon) Alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 05/15 | 05/15 | | |
NCT00747539: Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy |
|
|
| Completed | N/A | 330 | US | Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), Pegasys | University of California, Los Angeles, National Institute of Mental Health (NIMH) | HIV, Hepatitis C, Infections | 06/15 | 06/15 | | |
NCT01798576: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure |
|
|
| Terminated | N/A | 282 | Europe | Pegylated Interferon alfa-2a, Peginterferon alfa 2A, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 06/15 | 06/15 | | |
STANDART, NCT01609049: An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis |
|
|
| Completed | N/A | 1496 | RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 06/15 | 06/15 | | |
NCT01447446: An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C |
|
|
| Completed | N/A | 4442 | Europe, RoW | Peg-IFN Alfa-2a, Peg-IFN Alfa-2b, Ribavirin, Boceprevir, Telaprevir | Hoffmann-La Roche | Hepatitis C, Chronic | 07/15 | 07/15 | | |
NCT01659567: A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C |
|
|
| Completed | N/A | 516 | RoW | Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 10/15 | 10/15 | | |
NCT01604291: An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C |
|
|
| Completed | N/A | 991 | RoW | | Hoffmann-La Roche, Clalit Health Services | Hepatitis C, Chronic | 02/16 | 02/16 | | |
NCT01679834: An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C |
|
|
| Completed | N/A | 7500 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 07/17 | 07/17 | | |
